Clincosm LogoSign in Get a demo

refractory chronic lymphocytic leukemia

Showing 1 - 25 of 98
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 19, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)

Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 26, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duarte, California
  • +2 more
Oct 7, 2022

Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle

Terminated
Has Results
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Poland, United

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +6 more
  • Cincinnati, Ohio
  • +4 more
Aug 3, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jul 14, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United

Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Birmingham, Alabama
  • +4 more
May 10, 2022

Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
Apr 29, 2022

Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma Trial in United

Recruiting
  • Relapsed Chronic Lymphocytic Leukemia
  • +4 more
  • Phoenix, Arizona
  • +7 more
Apr 28, 2022

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
    • Bobigny, France
    • +8 more
    Mar 23, 2022

    Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small

    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +4 more
    • Jacksonville, Florida
      Mayo Clinic in Florida
    Mar 22, 2022

    Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

    Completed
    • Loss of Chromosome 17p
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 4, 2022

    Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia
    • +125 more
    • tetanus-CMV fusion peptide vaccine
    • laboratory biomarker analysis
    • Duarte, California
      City of Hope Medical Center
    Feb 28, 2022

    Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

    Active, not recruiting
    • Contiguous Stage II Small Lymphocytic Lymphoma
    • +11 more
    • MOR00208
    • +2 more
    • Columbus, Ohio
      The Ohio State University Comprehensive Cancer Center
    Feb 24, 2022

    Chronic Lymphocytic Leukemia, CLL, Relapsed CLL Trial (Dose combination 1-1, dose combination 1-2, Dose combination 1-3)

    Withdrawn
    • Chronic Lymphocytic Leukemia
    • +8 more
    • Dose combination 1-1
    • +5 more
    • (no location specified)
    Nov 1, 2021

    Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • Refractory Chronic Lymphocytic Leukemia
    • Bcl-2 Inhibitor GDC-0199
    • +5 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Oct 29, 2021

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

    Active, not recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • Scottsdale, Arizona
    • +1 more
    Aug 10, 2021

    B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic

    Terminated
    • B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
    • +16 more
    • Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    May 28, 2021